ArticleJournal of neuro-oncology2025
Stereotactic radiosurgery for patients with brain metastases from nasopharyngeal carcinoma.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe role of stereotactic radiosurgery (SRS) for patients with brain metastases from nasopharyngeal carcinoma (NPC) has yet to be established. The authors present a single-institution experience of NPC brain metastases patients who underwent SRS.
methodsOur SRS database of 18,000 patients from 1989 to 2024 identified 44 metastatic NPC patients (31 male) with 68 total brain metastases (median age: 58.5 years, range: 33-80). Twenty-four patients underwent whole brain fractionated radiation therapy (WBRT) and 20 patients underwent surgical resection before SRS. The median margin dose was 16 Gy (range: 10-25). The median cumulative tumor volume was 7.6 cubic centimeters (cc) (range: 0.032-186.66).
resultsThe median overall survival (OS) from SRS was 9 months (range: 0-86) with local tumor progression in 11 patients after SRS at a median time of 4 months (range: 2-36). Local tumor control was achieved in 56 of the 68 metastases (82.4%). Five patients developed new brain metastases at a median of 6 months (range: 3-84) following SRS. One patient experienced adverse radiation effects (AREs).
conclusionMetastatic spread to the brain from NPC occurs late in the course of primary disease. In our experience non-invasive SRS optimized outcomes and preserved quality of life. Although historically used as a salvage option after surgery and radiation therapy, its role as a primary strategy deserves further utilization in patients with brain metastases from primary NPC tumors.
Indexed as
Identifiers
41123716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.